Edgemond James, serving as Chief Financial Officer and Treasurer of United Therapeutics (NASDAQ:UTHR), carried out a planned sale of company stock on April 13, 2026, disposing of 8,559 shares for an aggregate amount of approximately $5.75 million. The sales took place in multiple executions at prices between $569.61 and $580.03 per share.
Also on April 13, James exercised stock options for 10,000 shares at an exercise price of $135.42, yielding a notional value of $1,354,199. The transactions were conducted under a Rule 10b5-1 trading arrangement that James established on October 31, 2025.
Following the completion of the sale, James is recorded as the direct owner of 18,876 shares of United Therapeutics. At the time referenced in company disclosures, UTHR was trading at $578.54 - a level close to its 52-week peak of $607.89 and after an approximately 103% advance over the prior 12 months.
Independent analysis cited in company reporting indicates that, on the metrics used by InvestingPro, the stock appears overvalued relative to its Fair Value. Readers are informed that a detailed Pro Research Report covering UTHR and more than 1,400 other U.S. stocks is available for those seeking deeper valuation context.
Alongside the insider transaction, United Therapeutics has seen a string of analyst actions and regulatory developments that pertain directly to its pipeline prospects. Raymond James initiated coverage, assigning an Outperform rating and noting the potential for Tyvaso to reach over $5 billion in peak sales for idiopathic pulmonary fibrosis. H.C. Wainwright raised its price target to $660, citing strong TETON-1 trial data that support Tyvaso’s growth into that indication.
BofA Securities increased its price target to $626 while keeping a Neutral stance, referencing positive Phase 3 results for Tyvaso. Jefferies moved its price target to $733 and adjusted its view on the probability of success for Tyvaso in idiopathic and progressive pulmonary fibrosis.
Regulatory news for the company includes the U.S. Food and Drug Administration granting Regenerative Medicine Advanced Therapy designation to United Therapeutics’ investigational liver device, miroliverELAP. The designation applies to a bioengineered liver device designed to provide temporary support for patients with acute liver failure.
Taken together, the insider selling and same-day option exercise, the share price near its annual high, valuation commentary from InvestingPro, and the series of analyst and regulatory updates present a snapshot of a company with active investor and regulatory attention. The developments outlined here reflect recent movements in United Therapeutics’ stock, management transactions, and external analyst and regulatory signals concerning its product pipeline.